73278-91-8

Basic information

• Product Name: [3-(PIPERIDINOMETHYL)PHENYL]METHANOL
• Synonyms: [3-(PIPERIDINOMETHYL)PHENYL]METHANOL;[3-(Piperidinomethyl)phenyl]methanol 90%
• CAS NO: 73278-91-8
• Molecular Formula: C₁₃H₁₉NO
• Molecular Weight: 205.3
• Mol File: 73278-91-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 67 °C
• Boiling Point: 324.3 °C at 760 mmHg
• Flash Point: 150.8 °C
• Appearance: /
• Density: 1.082 g/cm³
• Vapor Pressure: 0.000102mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: [3-(PIPERIDINOMETHYL)PHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(PIPERIDINOMETHYL)PHENYL]METHANOL(73278-91-8)
• EPA Substance Registry System: [3-(PIPERIDINOMETHYL)PHENYL]METHANOL(73278-91-8)

Safety Data

• Hazardous Substances Data: 73278-91-8(Hazardous Substances Data)

Usage

General Description

[3-(piperidinomethyl)phenyl]methanol, also known as PMPPM, is a chemical compound with the molecular formula C14H19NO. It is a white crystalline solid that is often used as a reagent in chemical research and in the synthesis of pharmaceuticals. PMPPM is a derivative of piperidine and phenylmethanol, and it is commonly used as a building block in the creation of complex organic molecules. Additionally, it has been studied for its potential pharmaceutical applications, particularly in the development of new drugs for various medical conditions. Due to its versatile chemical structure, PMPPM has a wide range of potential applications in both academic research and industrial settings.

InChI:InChI=1/C13H19NO/c15-11-13-6-4-5-12(9-13)10-14-7-2-1-3-8-14/h4-6,9,15H,1-3,7-8,10-11H2

Upstream product

• 104126-77-4 3-(piperidine-1-carbonyl)benzoic acid methyl ester 
• 52178-50-4 Methyl 3-formylbenzoate 
• 110-89-4 piperidine 
• 73278-90-7 methyl 3-[(piperidin-1-yl)methyl]-benzoate 
• 626-19-7 Isophthalaldehyde 

Downstream Products

• 473882-75-6 3-Piperidinomethylbenzylthiol 
• 471930-01-5 3-[(piperidin-1-yl)methyl]-benzaldehyde 
• 718591-77-6 1-(3-(chloromethyl)benzyl)piperidine 
• 73278-92-9 2-[[[3-[(1-piperidinyl)methyl]phenyl]methyl]thio]ethanamine 
• 104126-78-5 1-(3-(chloromethyl)benzyl)piperidine hydrochloride 

Relevant articles and documents

Synthesis and in Vitro Anticancer Activity of the First Class of Dual Inhibitors of REV-ERBβ and Autophagy

Autophagy inhibition is emerging as a promising anticancer strategy. We recently reported that the circadian nuclear receptor REV-ERBβ plays an unexpected role in sustaining cancer cell survival when the autophagy flux is compromised. We also identified 4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol, 1 (ARN5187), as a novel dual inhibitor of REV-ERBβ and autophagy. 1 had improved cytotoxicity against BT-474 breast cancer cells compared to chloroquine, a clinically relevant autophagy inhibitor. Here, we present the results of structure-activity studies, based around 1, that disclose the first class of dual inhibitors of REV-ERBβ and autophagy. This study led to identification of 18 and 28, which were more effective REV-ERBβ antagonists than 1 and were more cytotoxic to BT-474. The combination of optimal chemical and structural moieties of these analogs generated 30, which elicited 15-fold greater REV-ERBβ inhibitory and cytotoxic activities compared to 1. Furthermore, 30 induced death in a panel of tumor cell lines at doses 5-50 times lower than an equitoxic amount of chloroquine but did not affect the viability of normal mammary epithelial cells.

Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists

Recent bioisoteric replacements in histamine H3 receptor ligands with an exchange of the imidazole moiety by a piperidino group as well as of the trimethylene chain in 4-((3-phenoxy)propyl)-lH-imidazole derivatives (proxifan class) by an α,α′-xylendiyl linker represents the starting point in the development of 1-(4-(phenoxymethyl)benzyl) piperidines as a new class of nonimidazole histamine H3 receptor antagonists. According to different strategies in optimization of imidazole-containing antagonists the central benzyl phenyl ether moiety was replaced by numerous other polar functionalities. Additionally, the ortho- and meta-analogues of the lead were synthesized to determine the influence of the position of the piperidinomethyl substituent. The new compounds were tested in an in vitro binding assay for their affinities for cloned human H3 receptors stably expressed in CHO-K1 cells and for their oral in vivo potencies brain in a functional screening assay in the brain of mice. Additionally, activities of selected compounds were determined in the guinea-pig ileum functional test model. In contrast to the analogues ortho-substituted compounds all other compounds maintained respectable affinities for the human H 3 receptor (-logKi values 6.3-7.5). Despite the results from other classes of compounds the 4-methyl substituted derivatives generally displayed higher affinities than the corresponding 4-chloro substituted compounds. In vivo only the inverse phenyl benzyl ether (3) showed worthwhile antagonist potencies.

ANTIULCER BENZIMIDAZOLE DERIVATIVES

Compounds of formula I STR1 in which R 1 and R 2, which may be the same or different, are hydrogen, a C 1 to C 3 alkyl group or R 1 and R 2 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; R 3 and R. sub.4, which may be the same or different are hydrogen, a C 1 to C. sub.3 alkyl or an optionally substituted C 3 to C 6 cycloalkyl group, or R 3 and R 4 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; m is 0, 1 or 2; p is 0, 1 or 2; E is an alkylene group connected to or interrupted by an oxygen or a sulphur atom; J is hydrogen or a substituent group; and their pharmaceutically acceptable salts have utility as histamine H 2-receptor antagonists.